Utility of GnRH-agonists for fertility preservation in women with operable breast cancer: Is it protective?

被引：19

作者：

Bedoschi G. ^{[1
,2
]}

Turan V. ^{[1
,2
]}

Oktay K. ^{[1
,2
]}

机构：

[1] Laboratory of Molecular Reproduction and Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, NY

[2] Innovation Institute for Fertility Preservation, IVF, New York, NY 10028

来源：

Current Breast Cancer Reports | 2013年 / 5卷 / 4期

关键词：

Breast cancer; Chemotherapy; Clinical trials; Fertility preservation; GnRH agonist; Gonadal damage; Gonadal suppression;

D O I：

10.1007/s12609-013-0123-y

中图分类号：

学科分类号：

摘要：

Breast cancer is the most common type of malignancy in reproductive-age women. Breast cancer chemotherapy is associated with premature ovarian failure, infertility, and negative psychosocial effects related to these reproductive changes. As a result of this, fertility preservation becomes highly critical in this group of women. Besides the fertility preservation methods that utilize assisted reproductive technologies such as embryo, oocyte, and ovarian tissue cryopreservation, another suggested strategy for fertility preservation is suppression of ovarian ovulatory function by gonadotropin-releasing hormone agonist (GnRHa) administration before and during chemotherapy. However, both the efficacy and safety of GnRH agonists for prevention of ovarian damage are unproven and the preponderance of evidence indicates that this is an ineffective strategy. This review details the most recent information and studies on this controversial topic. © 2013 Springer Science+Business Media New York.

引用

页码：302 / 308

页数：6

共 42 条

[11]

Titus S., Li F., Stobezki R., Et al., Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans, Sci Transl Med, 5, (2013)

[12]

Braems G., Denys H., De Wever O., Cocquyt V., Van Den Broecke R., Use of tamoxifen before and during pregnancy, Oncologist, 16, pp. 1547-1551, (2011)

[13]

Davies C., Pan H., Godwin J., Et al., Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial, Lancet, 381, pp. 805-816, (2013)

[14]

Bedoschi G., Oktay K., Current approach to fertility preservation by embryo cryopreservation, Fertil Steril, 99, pp. 1496-1502, (2013)

[15]

Azim A.A., Costantini-Ferrando M., Oktay K., Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: A prospective controlled study, J Clin Oncol, 26, pp. 2630-2635, (2008)

[16]

Oktay K., Hourvitz A., Sahin G., Oktem O., Safro B., Cil A., Bang H., Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy, Journal of Clinical Endocrinology and Metabolism, 91, 10, pp. 3885-3890, (2006)

[17]

Ozkaya E., San Roman G., Oktay K., Luteal phase GnRHa trigger in random start fertility preservation cycles, J Assist Reprod Genet, 29, pp. 503-505, (2012)

[18]

Bedoschi G.M., De Albuquerque F.O., Ferriani R.A., Navarro P.A., Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: Case reports and review of the literature, J Assist Reprod Genet, 27, pp. 491-494, (2010)

[19]

Mature oocyte cryopreservation: A guideline, Fertil Steril, 99, pp. 37-43, (2013)

[20]

Greve T., Schmidt K.T., Kristensen S.G., Ernst E., Andersen C.Y., Evaluation of the ovarian reserve in women transplanted with frozen and thawed ovarian cortical tissue, Fertil Steril, 97, pp. 1394-1398, (2012)

← 1 2 3 4 5 →